Figure 6

Antibodies sensitize MALC to rapamycin. MALC were treated in the drop (a) or after 5 days of culture (b) with 10 μg/ml antibodies. Twenty-four hours later, MALC were treated with 50 nM of rapamycin. Every 5 days, cells were submitted to the same treatment. Results represent the percentage of cells in sub-G1 phase as determined by flow cytometry after DAPI staining at day 20 and are the mean of six independent experiments ±s.d. Asterisk represents significant differences between UT and anti-CD20 MAb/rapamycin treatment (P<0.05); Double asterisks represents significant differences between RTX/Rapa and GA101/Rapa treatment (P<0.05).